ARTICLE | Company News
Isis Pharmaceuticals, Eisai deal
August 19, 1996 7:00 AM UTC
The companies revised their 1990 agreement to develop ISIS 2922 (fomivirsen), an antisense compound in Phase III trials to treat cytomegalovirus (CMV) retinitis in AIDS patients (see BioCentury Extra...